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Abstract
Mammary epithelial stem cells are fundamental to maintain tissue
integrity. Cancer stem cells (CSCs) are implicated in both treat-
ment resistance and disease relapse, and the molecular bases of
their malignant properties are still poorly understood. Here we
show that both normal stem cells and CSCs of the breast are con-
trolled by the prolyl-isomerase Pin1. Mechanistically, following
interaction with Pin1, Notch1 and Notch4, key regulators of cell
fate, escape from proteasomal degradation by their major ubiqu-
itin-ligase Fbxw7a. Functionally, we show that Fbxw7a acts as an
essential negative regulator of breast CSCs’ expansion by restrain-
ing Notch activity, but the establishment of a Notch/Pin1 active
circuitry opposes this effect, thus promoting breast CSCs self-
renewal, tumor growth and metastasis in vivo. In human breast
cancers, despite Fbxw7a expression, high levels of Pin1 sustain
Notch signaling, which correlates with poor prognosis. Suppression
of Pin1 holds promise in reverting aggressive phenotypes, through
CSC exhaustion as well as recovered drug sensitivity carrying rele-
vant implications for therapy of breast cancers.
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Introduction
Breast cancer is the most frequently diagnosed cancer and the lead-
ing cause of cancer mortality in females worldwide (Siegel et al,
2011). Despite advances in diagnosis and treatment, a significant
percentage of breast cancer patients still die, due to the development
and dissemination of metastases (Steeg & Theodorescu, 2008). It is
increasingly acknowledged that a subpopulation of cancer cells,
termed cancer stem cells (CSCs) play a major role in cancer growth,
metastasis formation and chemoresistance (Dean et al, 2005; Stingl
& Caldas, 2007; Visvader & Lindeman, 2012). Like their normal
counterpart, CSCs are able to self-renew and maintain a reservoire
of cancer-initiating cells, that may produce a more differentiated
progeny of cells and contribute to intratumor heterogeneity (Stingl &
Caldas, 2007). This evidence has been observed for breast cancers,
where it has been shown that poorly differentiated, more aggressive
tumors (histological grade 3) have an increased number of CSCs
than well differentiated (histological grade 1) tumors (Pece et al,
2010).
Considerable similarities are found between normal and CSCs
regarding the molecular pathways and stem cell factors that deter-
mine the undifferentiated state of these cells, which suggested that
CSCs originate from the transformation of adult tissue stem cells or
from more differentiated progenitors that have acquired self-renewal
ability (Reya et al, 2001; Ben-Porath et al, 2008; Visvader & Lind-
eman, 2012). Several studies indicated that oncogenic activation of
pathways involved in the regulation of normal stem cells, such as
Notch, Wnt, SHH, RTKs, and PI3K/AKT among others, might be
involved in self-renewal properties and aggressive features of
CSCs (Polyak & Weinberg, 2009; Thiery et al, 2009; Visvader &
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Lindeman, 2012). However, how these signaling networks govern
CSCs still remains to be elucidated.
One appealing candidate as a fine-tuner of stem cell traits might
be the prolyl-isomerase Pin1. This unique enzyme catalyzes the cis/
trans conversion of specific motifs composed by phosphorylated Se-
rines or Threonines preceding a Proline in certain proteins, thereby
inducing conformational changes required for the full activity and
cross-talk of a plethora of signaling pathways (Liou et al, 2011).
Specifically, Serine/Threonine-Proline motifs (Ser/Thr-Pro) are
exclusive phosphorylation sites for a series of proline-directed kinas-
es, such as glycogen synthase kinase 3 beta, cyclin-dependent and
MAP kinases, that fulfill key roles in the control of signal trans-
duction.
The discovery of Pin1-catalyzed cis/trans isomerization of phos-
pho-Ser/Thr-Pro motifs revealed a post-phosphorylation mechanism
critical for several biological processes involved in physiology and
disease (Lu & Zhou, 2007; Yeh & Means, 2007). In particular, Pin1 is
required for full activity and cross-talk of a variety of oncogenic
pathways in breast and other cancers (Wulf et al, 2005), acting as
an amplifier of phosphorylation signals. Of note, deregulated levels
of Pin1 have been shown to disrupt cellular polarity of breast epithe-
lial cells (Ryo et al, 2002) and found associated to high tumor grade
and aggressiveness in breast cancer (Wulf et al, 2001; Girardini
et al, 2011). However, so far Pin1-dependent signaling mechanisms
have not been linked to breast CSCs’ biology.
In this work, by performing in vivo and in vitro functional stud-
ies in mouse models and cell lines, we show that Pin1 acts as a
fundamental regulator of stem cell features both in normal stem
cells and CSCs of the mammary gland. Pin1 controls CSC self-
renewal, replicative potential and frequency by antagonizing the
negative effect of Fbxw7a E3 ubiquitin-ligase on the Notch receptor
pathway, a fundamental regulator of cell fate frequently subverted
in breast cancer (Han et al, 2011; Ranganathan et al, 2011; Reedijk,
2012). At the biochemical level, we demonstrate that Notch1 and
Notch4 escape from Fbxw7a-dependent proteasomal degradation
following interaction with Pin1 and that phospho-specific prolyl-
isomerization of Notch1 triggers de-phosphorylation by the PP2A
phosphatase, preventing Fbxw7a interaction and subsequent poly-
ubiquitination. While mouse xenograft experiments prove the rele-
vance of Pin1 in tumor growth and metastasis formation in vivo,
gene expression and immunohistochemical analyses of primary
tumors from breast cancer patients show that Pin1 overexpression
is significantly linked to activated Notch, irrespectively of the coexi-
stance of functional Fbxw7a. Clinical implications of our findings
are relevant for breast cancer, since inhibition of Pin1 could sup-
press aggressive phenotypes through CSC exhaustion as well as
recovered sensitivity to chemotherapeutic drugs.
Results
The prolyl-isomerase Pin1 is required for the self-renewal of
normal mammary stem cells
Pin1 knock-out mice show a number of developmental defects (At-
chison & Means, 2004) affecting among others mammary epithe-
lium, that fails to undergo the dynamic changes required to its
expansion during pregnancy (Liou et al, 2002). Based on this,
we hypothesized a possible function of Pin1 in governing the
functions of mammary stem cells and thus we evaluated the stem
cell activity of mammary epithelial cells from wild-type (Pin1+/+)
and knock-out (Pin1/) mice. To this aim, mammary tissues from
8 to 10 weeks old virgin female mice were dissociated, prepared
as single cell suspensions of purified, lineage-depleted epithelial
cells (Sleeman et al, 2006; Stingl et al, 2006) and grown in sus-
pension cultures to form secondary mammospheres (M2) (Dontu
et al, 2003). Whereas cells obtained from Pin1+/+ mice formed an
average of 22.9 (1.44) M2 mammospheres per 100 000 seeded
cells, we observed a 40% reduction of M2 formation from Pin1/
cells (Fig 1A). In addition, to assess the impact of Pin1 on the rep-
licative potential of mammary stem cells, we serially replated
wild-type cells from primary mammospheres (M1) for four more
times (M2–M5) (Fig 1B). As expected in these conditions, we
observed a progressive decrease in mammosphere formation at
each passage, due to exhaustion of adult stem cells (Cicalese et al,
2009). Notably, this effect was significantly exacerbated by addi-
tion of the Pin1 small molecule inhibitor PiB (Uchida et al, 2003):
mammosphere formation efficiency of Pin1+/+ shrunk progres-
sively and was reduced by almost 50% at the stadium of quater-
nary mammospheres (M4) and did not reach the M5 level. This
evidence indicates a role for Pin1 in determining self-renewal and
replicative potential of mammary stem cells thus implying altera-
tions of the mammary stem cell compartment in Pin1/ mice. To
better characterize this aspect, we analyzed the proportion of stem
cells and progenitors by Flow cytometric analyses and sorting
(FACS) analysis using the surface markers CD24 and CD49f. These
markers are widely used to identify two populations of cells func-
tionally characterized as stem/bipotent progenitors (CD24med/
CD49fhigh or mammary repopulating units, MRU) and luminal pro-
genitors (CD24high/CD49flow or mammary colony forming cells,
Ma-CFCs) (Stingl et al, 2006). In line with our hypothesis, the
MRU and Ma-CFC cell populations from Pin1/ mammary glands
were present at lower proportion as compared to Pin1+/+ mice
(Fig 1C and supplementary Fig S1A). In addition, we found almost
three times higher Pin1 mRNA and protein levels in the MRU cell
population as compared to the total of mammary epithelial cells
(Fig 1D). This evidence confirmed our hypothesis and suggests a
prominent role of Pin1 in sustaining the mammary stem cell com-
partment in vivo.
Pin1 is required to sustain CSCs from mouse and human
mammary tumor cells
Stem cell traits in a subpopulation of mammary tumor cells are
thought to be implicated in treatment resistance (Dean et al, 2005)
and metastasis dissemination (Malanchi et al, 2012; Rosenthal et al,
2012; Visvader & Lindeman, 2012) and high levels of Pin1 correlate
with high grade breast cancer and chemoresistance (Wulf et al,
2001; Ding et al, 2008; Kim et al, 2009; Girardini et al, 2011). There-
fore we next chose to investigate whether Pin1 could also control
mammary CSCs. NOP6 mouse mammary tumor cells, harboring the
Her2/Neu amplification, were grown as mammospheres in presence
or absence of the Pin1 inhibitor (Fig 2A). NOP6 cells formed very
fast growing spheres that did not decrease when propagated to M3
or M4, indicating that mammosphere-forming cells were self-renew-
ing at a constant rate. Conversely, when cells were treated with
Pin1 inhibitor, mammosphere formation efficiency (MFE) was
strongly impaired already at the M2 level.
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We next tested whether Pin1 could be required for the mainte-
nance of human breast CSCs. To address this question, the MDA-
MB-231 breast cancer cell line expressing a doxycycline-inducible
knockdown costruct for Pin1 (pLKO-TetO-shPin1) was generated
and tested in mammosphere formation assays. As shown in Fig 2B
(left), in agreement with other reports (Harrison et al, 2010; Corde-
nonsi et al, 2011), non-induced cells had on average 0.6% of MFE,
remaining constant throughout serial replating to M4. Instead, in
Pin1 silenced (+DOX) cells, MFE decreased already at M2 stage




Figure 1. Pin1/ mice have decreased mammary epithelial stem/progenitor cells.
A Pin1/ mice display decreased self-renewal of mammary stem cells. Left panel: Number of secondary mammospheres (M2) generated from primary mammary
epithelial cells of indicated mice. Means, standard deviations and P-values (t-test, n = 4) are indicated in the histogram. Right panel: representative M2 microscope
images with 200 lm scale bar.
B Inhibition of Pin1 affects replicative potential of mammary stem cells. Serial replating of mammospheres (M1–M5) generated from Pin+/+ mice treated with DMSO or
PiB (1.5 lM).
C Bipotent stem cell and luminal progenitor number is decreased in Pin1/ mammary tissue. Left panel: representative FACS analyses of mammary epithelial cells
from indicated mice. CD24/CD49f plots and gatings for MRU and Ma-CFC populations are indicated. Right panel: histogram of mean counts of MRU and MA-CFC
populations from Pin/ normalized to Pin1+/+ mice. Means, standard deviations and P-values (t-test, n = 3) are indicated.
D Pin1 mRNA and protein levels are upregulated in the mammary stem cell compartment. Left panel: qRT-PCR of endogenous Pin1 mRNA in MRU sorted populations
relative to total population. Means, standard deviations and P-values (t-test, n = 3) are indicated. Right panel: Western blot analysis of the same cell populations as
in the left panel. Fold change in Pin1 protein levels determined by Image J software (Rasband, 1997–2012) with respect to actin levels is indicated by a number,
Molecular weights in kDa (Mr (K)) are shown on the right.
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inhibition shrunk mammosphere forming efficiency in a dose depen-
dent manner in MDA-MB-231 and other breast cancer cell lines (BT-
549 and SUM-159), (supplementary Fig S2A left and right). Pin1
inhibition impaired also self-renewal of CSCs derived from two
aggressive primary breast cancers (supplementary Fig S2B), demon-
strating that loss of Pin1 activity impairs breast CSC self-renewal
and replicative potential in a broad spectrum of breast cancer cells.
In fact, the content of putative stem cells was lower following Pin1
silencing or inhibition, as confirmed by the Aldefluor assay, that
evaluates the activity of Aldehyde dehydrogenase 1 (Aldh), a mar-
ker for breast CSCs (Ginestier et al, 2007) (Fig 2B, right). Con-
versely, overexpression of Pin1 by retroviral infection of MDA-MB-
231 cells increased M2 formation by almost twofold and produced
an increase of Aldh-positive cells compared to empty vector harbor-
ing cells (supplementary Fig S2C). In agreement with a role of Pin1
in the maintenance of breast CSCs, its mRNA levels were found up-
regulated in Aldh-positive as compared to Aldh-negative cells sorted
from MDA-MB-231 M2 (supplementary Fig S2D).
Digging deeper into the effects of Pin1 depletion, we next evalu-
ated the expression of several genes acting within pathways govern-
ing the stemness phenotypes of breast CSCs (Leong et al, 2007; Yu
et al, 2007, 2011; Polyak & Weinberg, 2009; Cordenonsi et al, 2011;
Visvader & Lindeman, 2012). As shown in Fig 2C (left panel), the




Figure 2. Pin1 inhibition strongly affects mouse and human mammary CSCs traits. (A) and (B) Means and standard deviations and P-values are indicated
(t-test, n = 3, M4).
A Pin1 inhibition decreases self-renewal of mouse mammary tumor cells. Serial replating of mammospheres (M1–M4) generated from NOP6 cells treated with DMSO or
PiB (1.5 lM). Mammosphere formation efficiency (%MFE) was calculated as percentage of mammospheres divided by the number of plated cells.
B Pin1 knockdown decreases self-renewal of human breast cancer cells. Left panel: MFE of MDA-MB-231-pLKO-shPin1 control cells (Ctrl) compared to shPin1 induced
cells (DOX) upon serial passages. Right panel: Quantification of Aldh-positive and Aldh-negative cells from control- and shPin1 induced M4, as assessed by FACS.
C Pin1 knockdown affects expression of stem cell markers. Left panel: qRT-PCR of the indicated stemness and EMT marker genes from MDA-MB-231-pLKO-shPin1
quaternary mammospheres (M4) upon shPin1 induction (DOX) with respect to control cells (Ctrl). Standard deviations are indicated, P-values * <0.02 (t-test, n = 3).
Right panel: Western Blot analysis of EMT markers of the same cells. Molecular weights Mr(K) are indicated in kDa. Representative microphotographs of M4 are
shown, 200 lm scale bar is indicated.
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ABCG2, Ptch, Bmi-1, HMGA2 and Klf4) decreased by Pin1 knock-
down.
Epithelial-mesenchymal plasticity in breast carcinoma has
recently been linked to acquisition of stem cell traits by tumor cells
(Mani et al, 2008). We therefore also analysed the impact of Pin1
modulation on this process by analyzing markers of epithelial-
mesenchymal transition (EMT). Of note, Pin1 downmodulation
caused enhanced mRNA expression of the epithelial marker
E-cadherin (CDH1) while that of mesenchymal markers Vimentin
and Fibronectin (VIM1, FN) was reduced (Fig 2C, left panel), in
parallel with a strong recovery of E-cadherin and decay of Slug and
Vimentin at the protein level (Fig 2C, right panel).
All together these results indicate that high Pin1 levels are
required to sustain mesenchymal traits and to keep pro-stemness
signaling constant.
Pin1 is required for Notch-dependent induction and
maintenance of stem cell self-renewal in normal and cancer
cells of the breast
The majority of genes described above are controlled by the Notch
pathway (Lee et al, 2008; Ranganathan et al, 2011; Li et al, 2012),
which was shown to be required for EMT induction (Leong et al,
2007) and regulation of both normal stem cells of the mammary
gland and breast CSC (Dontu et al, 2004; Bouras et al, 2008; Raouf
et al, 2008; Harrison et al, 2010; Xing et al, 2012). We therefore
investigated whether the action of Pin1 in breast CSCs maintenance
is driven by Notch function. Notch proteins are membrane-bound
receptors, that upon ligand binding, are subjected to cleavage by
gamma-secretase, releasing an intracellular domain (N-ICD) directly
involved in transcriptional control (Ranganathan et al, 2011). In
particular, two members of the family, Notch1 and Notch4, have
been linked to induction and maintenance of breast CSC features
(Farnie et al, 2007; Grudzien et al, 2010; Harrison et al, 2010).
Notably, the levels of their active forms (N1-ICD and N4-ICD) were
strongly reduced (about five fold) by Pin1 knockdown in M4 mam-
mospheres compared to control cells (Fig 3A). The robust downre-
gulation that we observed could not be totally ascribed to an
inefficient cleavage of Notch1 at the membrane due to Pin1 down-
modulation, as previously described (Rustighi et al, 2009). Rather,
since the Notch ICDs are tightly regulated by proteasomal degrada-
tion we hypothesized that Pin1 could regulate Notch ICDs’ stability.
To address the question whether the effect of Pin1 on breast CSC
relies on its action on N1-ICD levels, we tested the ability of wild-
type N1-ICD or of a constitutively stable N1-ICD mutant (dPEST) to
rescue M2 formation following Pin1 knockdown. This mutant lacks
the cdc4-phosphodegron constituting the consensus for the E3
ubiquitin-ligase Fbxw7a, the major negative regulator of the intra-
cellular Notch signal (O’Neil et al, 2007; Thompson et al, 2007). As
expected, M2FE of MDA-MB-231-pLKO-shPin1 cells decreased upon
Pin1 silencing (+DOX) (Fig 3B). Notably, M2FE did not further
increase following ectopic expression of N1-ICD in control cells,
since in these cells endogenous Notch pathway is already strongly
activated (Harrison et al, 2010). Moreover, N1-ICD overexpression
was not able to rescue M2FE in Pin1 silenced cells. By contrast,
overexpression of N1-ICD-dPEST was able to rescue M2FE. Consis-
tent with this, protein levels of over-expressed N1-ICD, but not
those of N1-ICD-dPEST, were strongly decreased upon Pin1 deple-
tion (Fig 3B, lower panel). Similar results were obtained in SK-BR-3
cells when N1-ICD or N1-ICD-dPEST were ectopically expressed and
the function of Pin1 blocked by the Pin1 inhibitor PiB (supplemen-
tary Fig S3A). These data suggest that Pin1 critically supports breast
CSC self-renewal by sustaining high intracellular levels of N1-ICD.
To strengthen this finding, we analysed the endogenous levels of
both Pin1 and N1-ICD in CSCs. To this aim, we sorted the Aldh-posi-
tive cells from MDA-MB-231 mammospheres or collected patient
derived mammospheres and analysed their protein content. As
shown in Fig 3C (left and right panels) in both conditions the pro-
tein levels of Pin1 and N1-ICD were almost two times higher in the
stem cell fraction as compared to those in their differentiated coun-
terpart. Moreover we found that also in vivo, in breast cancer tis-
sues, the expression of Pin1 colocalized with Aldh-positive cells
(supplementary Fig S3B).
We next tested whether Pin1 alone is sufficient to confer stem
cell traits in a Notch-dependent manner to a non-transformed epi-
thelial breast cell line. To this aim, we engineered MCF10A cells to
overexpress Pin1 and analysed them by FACS for expression of
CD44/CD24 surface molecules, two other well-established breast
stem cell markers (Al-Hajj et al, 2003). Pin1 overexpression caused
an enrichment of the CD44high/CD24low stem cell population as
compared to empty vector cells (supplementary Fig S3C). Accord-
ingly, while empty vector transduced MCF10A cells hardly formed
secondary mammospheres, Pin1 overexpression strongly induced
their formation (Fig 3D). This was accompanied by an EMT as dem-
onstrated by down- and upregulation of the two markers E-cadherin
and Slug, respectively. Crucially, the levels of cleaved Notch1 and
Notch4, normally undetectable in these cells, were upregulated by
Pin1 overexpression and were essential for mammosphere forma-
tion, since block of Notch cleavage by a gamma-secreatase inhibitor
(GSI) was sufficient to blunt this process (Fig 3D).
All together our results demonstrate that Pin1 is a bona fide stem
cell factor by promoting EMT and maintaining a mesenchymal/stem
cell fate mainly through regulation of the Notch pathway.
Suppression of Pin1 sensitizes breast CSC to chemotherapy
in vitro and in vivo
Breast CSCs and cells that have undergone an EMT exhibit increased
drug resistance (Dean et al, 2005; Gupta et al, 2009). In addition,
treatment of cancers with chemotherapeutic agents has been shown
to cause enrichment of CSCs (Yu et al, 2007; Levina et al, 2008).
This evidence prompted us to investigate the consequences of Pin1
ablation on breast CSCs’ drug resistance. To this aim we analysed
the efficiency of M2 formation of MDA-MB-231-pLKO-shPin1 cells
in presence of different chemotherapeutic agents (Fig 4A). As
expected, treatment of control cells with adriamycin, paclitaxel, iri-
notecan or methotrexate, elicited a slight increase or had no effect
on M2 formation. Instead, Pin1 silencing, which alone had already a
negative impact on mammosphere formation, elicited a strong syn-
ergistic toxicity in combination with all four compounds, as demon-
strated by the consistent drop of M2 formation efficiency in all
conditions.
To test the in vivo impact of these findings, we injected MDA-MB-
231 cells, stably expressing a control- or a Pin1-specific shRNA, into
the inguinal mammary fat pads of immunocompromised mice.
When tumors became visible, each group was randomized and trea-
ted with either paclitaxel or PBS and tumor growth was monitored
for two more weeks. As shown in Fig 4B, the size of Pin1 specific
ª 2013 The Authors EMBO Molecular Medicine Vol 6 | No 1 | 2014




Figure 3. Pin1 controls breast CSC self-renewal through N1-ICD stabilization.
A Pin1 depletion causes reduced N1- and N4-ICD protein levels. Left panel: Western Blot analysis of N1- and N4-lCD protein from MDA-MB-231-pLKO-shPin1 M4
control cells (Ctrl) and shPin1 induced cells (DOX). Molecular weights (Mr) are indicated in kDa. Right panel: histogram representing the percentage of band intensity
with respect to actin levels.
B Expression of N1-ICD-dPEST stable mutant rescues M2FE following Pin1 depletion. Upper panel: Percentage of secondary mammosphere formation efficiency (%
M2FE) of control (Ctrl, black bars) or Pin1 silenced (DOX, grey bars) cells, transduced with empty (), N1-ICD or N1-ICD-dPEST vectors (+). Means, standard deviations
and P-values (t-test, n = 3) are indicated. Middle panel: Western blot analysis of the indicated proteins from cells grown as M2. Lower panel: Scheme of protein
domains of overexpressed N1-ICD forms. Numbering refers to Swissprot entry P46531.
C Pin1 and N1-ICD levels are upregulated in the breast CSC compartment. Comparative Western blot analyses of Aldh-positive (stem) versus Aldh-negative cells (non-
stem) sorted from MDA-MB-231 M2 (left panel) and patient-derived breast cancer secondary M2 mammospheres (stem) versus cells cultured in adherence (2D) (right
panel). Relative fold change in Pin1 or N1-ICD protein levels determined by Image J software with respect to actin levels is indicated by a number.
D Pin1 overexpression promotes stem cell phenotypes through regulation of the Notch pathway. Upper panel: %M2FE of MCF10A breast epithelial cells transduced
with empty (pLPC) or HA-Pin1 overexpressing vectors (pLPC-HA-Pin1) and treated with DMSO () or 10 lM GSI. Means, standard deviations and P-values (t-test,
n = 3) are indicated. Middle panel: Representative microphotographs of M2 are shown, scale bar of 200 lm is indicated. Lower panel: Western Blot of cell lysates
from corresponding MCF10A clones. White and black arrows indicate over-expressed and endogenous Pin1, respectively.
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Figure 4. Pin1 downmodulation sensitizes breast CSCs to chemotherapeutic treatment in vitro and in vivo.
A Pin1 knockdown synergizes with chemotherapy treatment to block breast CSCs’ self-renewal. Percentage of M2FE of control MDA-MB-231-pLKO-shPin1 cells (Ctrl)
compared to shPin1-induced cells (DOX) treated with indicated drugs or PBS. Means and standard deviations are indicated, P-values are * = 0.001, **< 0.0003
(t-test, n = 3).
B Pin1 knockdown synergizes with paclitaxel to block breast cancer growth. Tumor growth of MDA-MB-231 xenografts espressing the indicated shRNAs and treated
with paclitaxel (grey bars) or left untreated (PBS) (black bars). Means and standard deviations are indicated, P-values are *** < 0.0003 (t-test, n = 12).
C Pin1 knockdown blocks chemotherapy-induced breast CSCs’ expansion in vivo. Histogram representing the Aldefluor mean fluorescent intensity (MFI) of cells from
control- and shPin1 MDA-MB-231 xenografts treated with Paclitaxel or PBS. Means and standard deviations are indicated, P-values are * = 0.001 (t-test, n = 3 for
each condition).
D Pin1 knockdown induces reversal of EMT and cell death in breast cancer xenografts in combination with paclitaxel. Western blot analyses of tumor xenografts from
(B).
E Expression of stable N1-ICD-dPEST rescues resistance to paclitaxel treatment in Pin1 silenced cells. Percentage of M2FE of control (black bars) or Pin1 shRNA (grey
bars) expressing MDA-MB-231 cells transduced with empty () or N1-ICD-dPEST (+) expressing vectors, treated with Paclitaxel (+) or PBS (). Means and standard
deviations are indicated, P-values are **0.0001, ***<0.00003 (t-test, n = 3).
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shRNA expressing tumors reached half of those with control shRNA
and treatment with paclitaxel induced a significant growth inhibition
in both conditions. We next analysed the CSC content (Aldh-pos) in
these tumors. As shown in Fig 4C, in paclitaxel treated control
tumors the Aldh-positive cell population was heavily increased with
respect to that derived from PBS treated xenografts (Fig 4C). In con-
trast, tumors in which Pin1 was silenced were characterized by a
drastic impoverishment of Aldh-positive CSCs in both treatment con-
ditions, indicating that high Pin1 levels are required for chemother-
apy-induced CSCs expansion. We next analysed protein lysates from
these tumors by Western blot. As shown in Fig 4D, we detected a
reversal of the EMT phenotype in shPin1 expressing tumors, as evi-
denced by increased E-cadherin and decreased Slug and Vimentin
levels. Accordingly, N1-ICD levels were downregulated in these
tumors. In addition, paclitaxel treatment induced caspase-3 cleavage
that was strongly increased by Pin1 silencing, indicating that
reduced levels of Pin1 synergize with paclitaxel in inducing apopto-
sis and hence causing maximal tumor shrinkage. Mcl-1 is an impor-
tant mediator of paclitaxel resistance in breast cancer and other
tumors and a critical prosurvival protein (Ding et al, 2008; Inuzuka
et al, 2011; Wertz et al, 2011). Being also stabilized by Pin1 (Ding
et al, 2008), we wondered whether Mcl-1 downmodulation could be
involved in apoptosis induction upon Pin1 silencing and paclitaxel
treatment. This experiment indicated that Mcl-1 levels were indeed
affected either by Pin1 silencing or paclitaxel treatment. However, in
xenografts silenced for Pin1 and treated with paclitaxel, we did not
observe further changes in Mcl-1, indicating that other important
mediators of chemoresistance were involved in this context. Never-
theless, these effects appeared to be Notch-dependent, since MDA-
MB-231 cells treated with two different Pin1 shRNAs and transduced
with a N1-ICD-dPEST expressing vector were able to fully regain
chemoresistance, as shown by recovery of M2FE in presence of the
chemotherapeutic agent (Fig 4E and supplementary Fig S4A).
All together these results indicate that Pin1 is crucial in maintain-
ing the self-renewal and replicative potential of both normal stem
cells and CSCs of the mammary gland and that genetic or pharmaco-
logical ablation of Pin1 impairs their expansion with a strong effect
in CSCs, eliciting sensitivity to chemotherapeutic drugs.
Pin1 regulates N1-ICD stability through the cdc4-phosphodegron
We next analyzed in more detail the impact of Pin1 on N1-ICD pro-
tein stability. As shown in Fig 5A, Pin1 depletion by siRNA in MDA-
MB-231 breast cancer cells treated with gamma-secretase inhibitor
to blunt Notch cleavage at the membrane (Ranganathan et al,
2011), caused a strong decay of cytoplasmic N1-ICD. This effect was
proteasome-dependent since N1-ICD levels were rescued following
addition of the proteasome inhibitor Lactacystin. Also in the SK-BR-
3 breast cancer cell line the half-life of overexpressed N1-ICD was
strongly reduced from 2 h to 40 min upon Pin1 siRNA treatment
with respect to control silencing (supplementary Fig S5A). Impor-
tantly, reintroduction of a siRNA resistant Pin1 construct (Pin1r) in
Pin1 depleted cells almost completely reversed this effect, demon-
strating that N1-ICD levels are Pin1 dependent.
Pin1 is known to bind several substrates on phosphorylated TP
or SP residues and to affect their stability (Liou et al, 2011).
In vitro and in vivo binding experiments demonstrated that Pin1
binds to N1-ICD and this interaction was direct (supplementary Fig
S5B and C). Moreover, domain mapping analysis showed a marked
reduction in Pin1 binding to N1-ICD when the C-terminal PEST
domain containing the cdc4-phosphodegron was deleted (supple-
mentary Fig S5D). Intriguingly, the residues T2512/P2513 within
the phosphodegron, known to be critical for recognition by the
ubiquitin-ligase Fbxw7a upon phoshorylation of T2512 (O’Neil
et al, 2007; Thompson et al, 2007), might also become a Pin1 bind-
ing site. Indeed, when we performed in vitro GST-Pin1 binding
assays with N1-ICD or a point mutant replacing the threonine resi-
due 2512 with alanine (T2512A), the interaction was decreased
(supplementary Fig S5E). Moreover Pin1 overexpression did not
affect the levels of this mutant in protein stability assays, as it did
instead with wild-type N1-ICD (supplementary Fig S5F). All together
these results raise the possibility that, when phosphorylated, amino-
acids T2512/P2513 constitute the docking site for Pin1, which might
exert N1-ICD stabilization by interfering with Fbxw7a-binding.
Pin1 sustains N1- and N4-ICD levels in vitro and in vivo despite
expression of Fbxw7a
To test whether the accumulation of nuclear N1-ICD could depend
on the ability of Pin1 to antagonize Fbxw7a recognition and activity
on N1-ICD, we evaluated the effect of Pin1 on Fbxw7a-dependent
poly-ubiquitination of N1-ICD by Ni-NTA pull down in COS-7 cells
(Fig 5B). As expected (O’Neil et al, 2007; Thompson et al, 2007),
co-transfection of N1-ICD and Fbxw7a caused an enhancement of
poly-ubiquinated N1-ICD as compared to empty vector control. Con-
versely, simultaneous depletion of Pin1 markedly increased ubiqu-
itin conjugation, demonstrating that Pin1 antagonizes Fbxw7a-
mediated N1-ICD poly-ubiquitination. Moreover, in MDA-MB-231
cells, reduced N1-ICD levels caused by Pin1 knockdown, were
recovered by concomitant Fbxw7a silencing, thus indicating that
Pin1 action was epistatic to Fbxw7a for N1-ICD stabilization (sup-
plementary Fig S5G). Accordingly, when N1-ICD and Fbxw7a were
ectopically expressed in SK-BR-3 cells and in Pin1/ mouse embryo
fibroblasts, introduction of Pin1 efficiently rescued N1-ICD levels in
the presence of the E3 ubiquitin-ligase (Fig 5C and supplementary
Fig S5H). Moreover, N1-ICD stabilized by Pin1 over-expression was
fully efficient at inducing transcription of target promoters, despite
presence of functional Fbxw7a (supplementary Figs S5I and J).
The cdc4-phosphodegron is present also in N4-ICD (supplemen-
tary Fig S5K, upper part) and has been shown to be targeted for deg-
radation by Fbxw7a (Wu et al, 2001). Pin1 bound efficiently also to
N4-ICD, and silencing of Pin1 accelerated N4-ICD’s proteasome-
dependent degradation (supplementary Fig S5K, middle and lower
panels). Accordingly, Pin1 over-expression enhanced both the levels
and transcriptional activity of N4-ICD towards RBP-Jj/LUC in the
presence of over-expressed Fbxw7a (supplementary Fig S5L).
To confirm in vivo that N1- and N4-ICDs levels were
Pin1-dependent we performed immunohistochemical analyses of
mammary ducts from 8 weeks old virgin Pin1+/+ and Pin1/
mice. Supplementary Fig S5M clearly shows that while endogenous
Fbxw7a protein levels remained unperturbed, the staining of both
nuclear Notch1 and Notch4 was lower in Pin1/ mammary ducts
as compared to those of Pin1+/+ mice. These results were quantita-
tively confirmed by Western blot analyses of mammary epithelial
cell lysates obtained from Pin1+/+ and Pin1/ mammary ducts
(Fig 5D).
Pin1 was previously shown to be a direct transcriptional
target of N1-ICD (Rustighi et al, 2009), therefore we asked if
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N4-ICD might be a Pin1 regulator as well. By performing chro-
matin-immunoprecipitation and luciferase assays of the human
Pin1 promoter (supplementary Figs S5N and O) we demonstrated
that Pin1 is a direct N4-ICD transcriptional target. All together
these data demonstrate in vitro and in vivo that Pin1 is critical
for regulating the levels of both N1 and N4-ICDs. Moreover the
degradation of both N1- and N4-ICDs by Fbxw7a can be effi-
ciently overcome by Pin1, which restores their functional tran-
scriptional activity, demonstrating the existence of a feed-forward
molecular circuitry between Pin1 and the intracellular forms of
both Notch1 and Notch4.
Pin1 isomerase activity protects N1-ICD from Fbxw7a-
dependent degradation
To dissect the molecular mechanism governing the antagonistic
interplay between Pin1 and Fbxw7a, we investigated the impact
of Pin1 on the N1-ICD-Fbxw7a or N4-ICD-Fbxw7a association.
As judged by co-immunoprecipitation (Co-IP) experiments per-
formed with both endogenous and overexpressed proteins, we
consistently observed increased binding between Fbxw7a and
N1-ICD or N4-ICD upon inhibition of Pin1 activity by the small
molecule inhibitor PiB (Fig 6A and supplementary Fig S6A) or
depletion by siRNA (Fig 6B and supplementary Fig S6B). Impor-
tantly, in Pin1/ mouse embryo fibroblasts, expression of Pin1,
but not of the catalytic inactive mutant Pin1S67E (Rustighi et al,
2009), reduced their association (Fig 6C). Like wild-type Pin1,
Pin1S67E interacts with N1-ICD (supplementary Fig S6C), there-
fore these data clearly indicate that it is the isomerase activity
of Pin1 that is crucial to oppose N1-ICD-Fbxw7a interaction, rul-
ing out the possibility of a mere competition between the two
enzymes for binding to the phosphorylated sites within the cdc4-
phosphodegron.
Prolyl-isomerization of specific phospho-S/T-P sites leads, on
certain substrates, to recognition and subsequent dephosphorylation
by the trans-specific phosphatase PP2A (Liou et al, 2011). We there-
fore hypothesized that, following isomerization by Pin1, the Notch
cdc4-phosphodegron could be dephosphorylated by PP2A, thus
eluding recognition by Fbxw7a. To evaluate this possibility we
assessed the interaction between N1-ICD and Fbxw7a by co-imuno-
precipitation in SK-BR-3 cells treated with PP2A inhibitor okadaic
A B
DC
Figure 5. Pin1 rescues N1- and N4-ICD from Fbxw7a-mediated proteasome-dependent degradation. Molecular weights (Mr) are indicated in kDa.
A Pin1 knockdown accelerates the decay of endogenous N1-ICD. Western blot of endogenous N1-ICD following RNA interference (RNAi) with the indicated siRNAs and
time points following GSI or GSI plus Lactacystin (+) chase is shown.
B Pin1 depletion enhances Fbxw7a-dependent poly-ubiquitination of N1-ICD. Western blot analysis of high molecular weight N1-ICD-myc products (N1-ICD-myc[Ub]n)
from a Ni-NTA pull-down in COS-7 cells transfected with the indicated vectors along with control- or Pin1 siRNA. Input levels of over-expressed proteins are shown.
C Pin1 overexpression rescues N1-ICD levels in presence of Fbxw7a. Western blot analysis of lysates from SK-BR-3 cells over-expressing N1-ICD-myc, Flag-Fbxw7a along
with empty () or increasing amounts of HA-Pin1 expressing vector, normalized for co-expressed GFP protein.
D Pin1/ mammary epithelial cells have impaired Notch pathway activation. Western blot analyses of primary MECs from indicated female mice.
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acid or silenced for PP2A expression. As shown in Fig 6D and sup-
plementary Fig S6D, the interaction between N1-ICD and Fbxw7a
increased when cells were treated with okadaic acid or upon PP2A
silencing, with consequent reduction of the levels and half-life of
endogenous N1-ICD (Fig 6E). We next analyzed the dynamics of
this interaction following Pin1 overexpression in the same condi-
tions as above. As shown in Fig 6F and supplementary Fig





Figure 6. Pin1 controls N1-ICD half-life by uncoupling it from Fbxw7a. Experiments in (A)-(D) and (F) were performed in presence of proteasome inhibitor to
avoid misinterpretation of binding results due to protein degradation. (A–F) Molecular weights (Mr) are indicated in kDa.
A Inhibition of Pin1 increases interaction between endogenous Fbxw7a and N1-ICD proteins. Western blot analysis of co-immunoprecipitation (Co-IP) experiments
between endogenous Fbxw7a and N1-ICD from MDA-MB-231 cells treated with DMSO () or PiB (+). Anti-Fbxw7a or non related antibody (NRA) immunoprecipitates
(IP) were recognized with anti-N1-ICD (Val1744) antibody and after stripping with an anti-Fbxw7a antibody. Input levels are shown below.
B Depletion of Pin1 increases Fbxw7a-N1-ICD interaction. Representative Western blot analysis of Co-IP experiments between over-expressed N1-ICD-myc and Flag-
Fbxw7a in SK-BR-3 cells. Over-expressed N1-ICD-myc was immunoprecipitated (IP) and subjected to anti-Flag Western Blot to reveal Flag-Fbxw7a Co-IP. Input levels
of over-expressed or silenced proteins are shown below.
C Pin1 catalytic activity is required to uncouple N1-ICD from Fbxw7a. Co-IP as in (B) in Pin1/ embryo fibroblasts transduced with the indicated vectors.
D Inhibition of PP2A enforces Fbxw7a-N1-ICD interaction. Co-IP as above in SK-BR-3 cells treated with DMSO () or okadaic acid and transduced with the indicated
vectors.
E Inhibition of PP2A accelerates the half-life of endogenous N1-ICD. Western blot analysis of a GSI chase of MDA-MB-231 cells treated with vehicle (DMSO) or okadaic
acid. Anti-p21Cip1Waf1 immunoblot was added as control for Okadaic acid functioning (Park et al, 2001).
F PP2A is required for Pin1-dependent N1-ICD detachment from Fbxw7a. Co-IP as above in SK-BR-3 cells transduced with the indicated vectors and treated with DMSO
() or okadaic acid.
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N1-ICD and Fbxw7a but only in the presence of functionally active
PP2A, indicating that PP2A is required for Pin1-dependent N1-ICD
accumulation.
Pin1 and Fbxw7a control Notch1/4-dependent stem cell self-
renewal and frequency in an antagonistic fashion
Having dissected the biochemistry of the Pin1/Fbxw7a antago-
nism in the Notch pathway, we next investigated the impact of
this interplay on the stem cell functions of Notch signaling in
breast cancer cells. We performed secondary mammosphere (M2)
formation assays in MDA-MB-231 cells ectopically expressing
Fbxw7a and Pin1. As shown in Fig 7A and supplementary Fig
S7A, the efficiency of mammosphere formation, the levels of both
N1- and N4-ICD and the size of the Aldh-positive cell population
were all curbed in Fbxw7a over-expressing cells as compared to
the empty vector control. Of note, this effect was almost com-
pletely rescued by simultaneous expression of Pin1, which recov-
ered both N1- and N4-ICD protein levels and transcriptional
activity towards endogenous targets (HES-1 and Pin1, Fig 7A,
right panel). These effects were Notch-dependent, as indicated by
the decrease, in all conditions, of M2 formation efficiency upon
administration of GSI or Notch1 specific siRNA (Fig 7A and sup-
plementary Fig S7B).
As shown above, Fbxw7a had a potent inhibitory effect on CSCs.
Since Fbxw7a acts on several important targets (Wang et al, 2011)
we assessed the relevance of Notch activity for this phenotype. As
shown in Fig 7B downmodulation of Fbxw7a caused a consistent
increase of N1-ICD levels and spured M2FE and treatment with GSI
elicited a strong reduction of both mammosphere formation and
Notch pathway activation (Fig 7B and supplementary Fig S7C), thus
demonstrating that among several Fbxw7a targets, Notch is the criti-
cal one in this cellular context.
Next, to demonstrate the impact of Pin1 and Fbxw7a interplay
on CSC frequency in vivo, we injected increasingly diluted single-
cell preparations in the inguinal mammary gland of SCID mice
(Table 1). At 300 000 transplanted cells, only MDA-MB-231 cells
transduced with empty vector still developed palpable tumors in all
mice, while Fbxw7a over-expressing cells originated tumors in only
two out of nine. Cells overexpressing Pin1 and Fbxw7a, instead,
showed a significant recovery of tumor formation, since tumors
grew in seven out of nine mice, a trend that was observed also for
the subsequent dilution of 150 000 cells.
We further explored the behavior of these cells in tumor growth
and dissemination in vivo. To this aim, we injected 1 000 000 cells/
flank to allow tumor formation in all transplanted mice. Compared
to control, MDA-MB-231 cells overexpressing Fbxw7a produced
A
B
Figure 7. Pin1 and Fbxw7a modulate N1-ICD stem cell activity in vitro.
A Fbxw7a overexpression reduces breast CSCs self-renewal. Left panel: %M2FE of MDA-MB-231 cells overexpressing the indicated vectors. Black and grey bars indicate
DMSO or GSI treated mammospheres, respectively. Means, standard deviations and P-values (t-test, n = 3), are indicated. Middle panel: Representative
microphotographs of M2 are shown, 200 lm scale bar is indicated. Right panel: Western Blot of cell lysates from M2. White and black arrows indicate over-expressed
and endogenous Pin1, respectively.
B Fbxw7a genetic ablation increases breast CSCs’ self-renewal in a Notch-dependent manner. Left panel: Histogram showing %M2FE of MDA-MB-231 cells with
indicated siRNA and treated with vehicle (black bars) or GSI (grey bars). Means, standard deviations and P-values (t-test, n = 3), are indicated. Right panel: Western
Blot of cell lysates from M2. Molecular weights (Mr) are indicated in kDa.
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only small tumors with decreased levels of N1-ICD, reduced expres-
sion of a series of Notch1 target genes, loss of mesenchymal and
recovery of epithelial markers (Fig 8A–C and supplementary Fig
S8A). Conversely, Pin1 overexpression bypassed the tumor suppres-
sor function of Fbxw7a, as demonstrated by tumors co-expressing
both proteins, that displayed increased volume, rescued N1-ICD lev-
els, its transcriptional activity on target genes as well as the levels of
mesenchymal markers. Consistently, Pin1 overexpression in
Fbxw7a overexpressing cells recovered also the ability of tumors to
develop metastasis into nearby lymph nodes and to the lungs
(Fig 8D and E).
Aberrant Notch signaling in primary breast cancers is sustained
by Pin1 in spite of Fbxw7a expression
In human T-cell acute lymphoblastic leukaemia and lymphoma
(T-ALLs) aberrant Notch activity is caused by mutations of NOTCH1
and FBXW7 in more than 50% of patients (Ferrando, 2009). Like in
T-ALLs, also in human patients with breast cancer high expression
of Notch receptors and ligands is causally involved and has been
linked to poor clinical outcomes (Han et al, 2011; Xu et al, 2012).
However, according to Cosmic, CONAN and TCGA databases and
recent publications, these genes are rarely mutated in breast cancer
(ranging from 2 to 8% depending on the analysis) (Byrd et al, 2008;
Mao et al, 2008; Ibusuki et al, 2011; Santarpia et al, 2012), raising
the possibility that in this context, in the absence of mutations, high
Pin1 expression might contribute to sustain levels and function of
nuclear N1- and N4-ICD by interfering with their degradation by
Fbxw7a.
To evaluate this hypothesis, we analysed tissue sections from
two groups of breast cancer patients. The first derived from 43
breast cancers, previously characterized for the amount of activated
N1-ICD protein by IHC (Vermezovic et al, submitted) and the sec-
ond group consisting of 38 breast cancer tissues of the triple nega-
tive (TNBC) subtype. The first group was analysed by quantitative
RT-PCR for the expression levels of PIN1 and FBXW7 mRNA (sup-
plementary Fig S9A, and B), known to provide a direct correspon-
dence to their protein levels (Girardini et al, 2011; Ibusuki et al,
2011). Samples were grouped into high or low N1-ICD expressing
cases and, in agreement with previous IHC data on other cohorts
(Farnie et al, 2007; Rustighi et al, 2009), N1-ICD levels were high in
40% (17/43 cases) of the analyzed tumors (supplementary Fig
S9A). Of note, in 65% of these cases (11/17 cases) we found also
high FBXW7 expression. Strikingly, all the samples simultaneously
displaying high N1-ICD and high FBXW7 expression, also expressed
high levels of PIN1 (supplementary Fig S9A and B), indicating that
in a consistent proportion of breast cancer patients (11/43 cases)
high N1-ICD levels coexist with Fbxw7a thanks to high Pin1 expres-
sion.
We next stained serial sections of the second group (38 TNBC
samples) of breast cancer tissues with anti-N1-ICD, anti-Pin1 and
anti-Fbxw7 antibodies (Fig 9A and supplementary Fig S9C). Among
22 patients with high intracellular Notch1 immunoreactivity we
found a high percentage of patients with a strong nuclear Fbxw7a
signal (72.7%). Again, the majority of these samples (93.8%) also
displayed high Pin1 levels, that might be responsible for the simulta-
neous presence of high N1-ICD and its ub-ligase (Fig 9A and supple-
mentary Fig S9C).
We finally confirmed these results on a larger cohort of patients
by analyzing a meta-dataset of 19 independent breast cancer expres-
sion studies, collectively consisting of 3254 individuals (see supple-
mentary Data S1 and Table S1). Specifically we used the classifier
described in Adorno et al (2009) to stratify patients into groups of
tumors expressing high or low levels of FBXW7 and PIN1 mRNA.
Considering that mRNA levels of Notch receptors are frequently not
representative of the protein levels of N1-ICD, activated Notch1
pathway status in this cohort was inferred from expression levels of
a Notch-dependent gene signature, built up by selecting published
Notch1 targets, for which Notch responsiveness and/or direct pro-
moter binding as well as their expression in breast cancer was dem-
onstrated (Notch direct target gene signature, NDT, supplementary
Table S2). More than 48% of all samples expressed high levels of
NDT signature genes and this correlated with poorer overall survival
(Fig 9B and supplementary Fig S9D), consistent with previously
published analyses (Farnie et al, 2007) and confirming the useful-
ness of this signature as a surrogate of activated Notch1 pathway.
Interestingly, we found high FBXW7 levels expression in 51.7% of
patients with hyperactive Notch (Fig 9B). Similarly to the findings
in the cohorts of Fig 9A and supplementary Fig S9A, we found a
high correlation with PIN1 overexpression in the great majority of
these cases, while those with low PIN1 expression were underrepre-
sented with respect to any other possible category of patients
with high levels of FBXW7 mRNA (Fig 9B). Notably, the average
Table 1. Frequency of CSCs in MDA-MB-231 xenografts.
1 000 000 600 000 300 000 150 000
Empty 6/6 9/9 9/9 12/15
Fbxw7a 6/6 9/9 2/9 1/15
Fbxw7a + Pin1 6/6 7/8 7/9 5/15
Estimate (0.95) Lower–Upper P value P value
Empty 1:144 232 1:84 380–1:49 364
Fbxw7a 1:776 940 1:485 184–1:302 989 1.58 × 106
Fbxw7a + Pin1 1:466 587 1:302 232–1:195 771 1.04 × 102 0.0239
Mice were transplanted with decreasing numbers of MDA-MB-231 cells overexpressing empty, Fbxw7, or Fbxw7 + Pin1 vectors (number of injected cells is
indicated). Results are shown as the number of tumors per number of injected mice (upper panel). CSC frequencies (estimates and upper/lower limits) were
calculated by limiting dilution analysis, as described in Materials and methods. Differences in CSC frequencies are indicated for each sample against the empty
vector and for Fbxw7 + Pin1 against Fbxw7 only. Their significance is indicated by a P value (lower panel).
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Figure 8. Pin1 and Fbxw7a modulate N1-ICD stem cell activity in vivo. (A), (B) and (D), (E) Means, standard errors of the mean and P-values (t-test, n = 6), are
indicated. (C) Molecular weights Mr(K) are indicated in kDa.
A Pin1 rescues tumor growth in Fbxw7 overexpressing xenografts. Tumor volume of orthotopic xenografts in SCID mice obtained from the indicated MDA-MB-231 cell
clones.
B Pin1 rescues stem cell marker expression in Fbxw7 overexpressing xenografts. qRT-PCR of Fbxw7a and Fbxw7a + Pin1 tumor xenografts relative to control tumors
(empty) explanted at the end of the experiment.
C Pin1 recovers EMT marker expression in Fbxw7 overexpressing xenografts. Western blot analyses of the indicated proteins from the same tumor xenografts as in (A).
D,E Pin1 rescues metastasis formation of Fbxw7 overexpressing primary tumors. Comparison of lymph node and pulmonary metastases growth derived from the above
xenografts, respectively. Representative images of colonized lymph nodes (D) and hematoxylin and eosin stained pulmonary sections (E) are shown. Rulers and
Scale bars (1 mm) are indicated for calibration, arrows indicate metastatic areas.
F Schematic representation summarizing the role of Pin1 in sustaining CSCs through Notch1 and Notch4 by antagonizing Fbxw7a-mediated destruction.
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expression value of NDT gene signature was contingent on PIN1
mRNA levels (Fig 9C), while FBXW7 was non influential, therefore
highlighting the biological dominance of Pin1 over Fbxw7a in regu-
lating Notch signaling in breast cancer. To evaluate the clinical sig-
nificance of this finding we searched for the effect of high or low
Pin1 expression levels on the survival of patients with high or low
NDT signature. While Pin1 levels did not affect the clinical outcome
in all patients, we found that in grade 3 breast cancer high Pin1 lev-
els correlate with a worse outcome in patients with activated Notch1
signature (high NDT-high PIN1, Fig 9D), but not in patients with
low NDT signature expression (supplementary Fig S9E). Moreover,




Figure 9. High N1-ICD levels in human breast cancers coexist with Fbxw7 thanks to high Pin1 expression.
A Immunohistochemical analysis of the indicated proteins in a panel of 38 triple negative breast cancer samples. Upper panel: heatmap representing the protein levels
of Pin1, Fbxw7a and N1-ICD in a cohort of 38 breast cancer patients. The colors represent high (red) or low (blue) protein levels according to protein expression scores
(see supplementary Methods). Lower panel: Contingency table showing percentage of each category calculated on the precedent category of patients; chi-square test
was performed for independence between the variables and the P-value = 105.
B NDT expression analysis in a Meta-dataset of 3254 breast cancer patients. Upper panel: heatmap representing the contingency table frequencies of samples classified
as having high or low levels of FBXW7, of PIN1 and of the NDT gene signature. Number of samples in each category is indicated on the left. The association among
high levels of NDT gene signature, PIN1, and FBXW7 resulted statistically significant (P < 0.001; chi-square test). Lower panel: Contingency table showing percentage
of each category calculated on the precedent category of patients.
C Expression correlation between NDT and PIN1 and FBXW7 mRNA levels. Average expression of NDT gene signature in breast cancer samples stratified according to
high or low expression of PIN1 and FBXW7 mRNA. Data are shown as mean  standard error of the mean (s.e.m.).
D Survival analysis of Grade 3 high NDT expressing patients in function of PIN1 expression. Kaplan–Meier survival curve is indicated for high NDT signature, grade 3
breast cancer patients of the metadataset in function of high or low PIN1 mRNA levels. P-value and the number of subjects at risk at each time point is indicated
below.
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pathway signature genes in this group of patients (high NDT-high
PIN1, supplementary Table S3).
Discussion
A consistent body of evidence accumulated in the past years sup-
ports the relevance of Pin1-mediated prolyl cis/trans isomerization
in controlling the fate of phosphoproteins, hence a wide spectrum of
cellular events (Liou et al, 2011). In this study a novel role for this
unique isomerase is highlighted in the maintainance of stem cell
traits of both normal SCs and CSCs of the breast.
Normal and CSCs manifest considerable similarities regarding
the molecular pathways and factors that determine their undifferen-
tiated state and their expansion (Visvader & Lindeman, 2012). We
present here a scenario in which, through modulation of Notch sig-
naling, Pin1 fine-tunes stem cell pathways in the normal gland and
is fundamental for the induction of mouse and human mammary
CSCs. Reduction of its levels, or inhibition of its activity, in this con-
text, is sufficient to revert stem cell traits and rescue sensitivity to
chemotherapeutic agents in vitro and in vivo. We have also shown
that stem cell and EMT markers are subjected to Pin1 levels, provid-
ing a molecular basis for the observed phenotypes.
It has been shown that Pin1 and Notch1 are mediators of chemo-
resistance (Ding et al, 2008; Ranganathan et al, 2011; Domingo-Do-
menech et al, 2012), another critical trait of CSCs. Notch1, in
particular, plays a major role in this process, since it promotes the
expression of cell survival (e.g. BIRC5 or SURVIVIN and BCL-2) and
drug efflux pump genes (e.g. ABCG2) (Bhattacharya et al, 2007;
Ranganathan et al, 2011). It is conceivable that the regained sensi-
tivity of CSCs to drug treatment that we observed in vitro and in vivo
by downregulation of Pin1 could be the consequence of reduced cell
survival and drug efflux that are under direct control of Notch1
(Fig 4).
In our animal models, the stemness properties governed by Pin1
and Notch1 match well with their tumorigenic and metastatic poten-
tial. In parallel, in G3 breast cancers, high Pin1 levels are associated
with a worse clinical outcome in patients with high NDT signature
(Fig 9D). Pin1 levels have been clearly demonstrated to correlate
with tumor grade (Wulf et al, 2001). This evidence coupled with the
observation that G3 aggressive and poorly differentiated tumors,
characterized by bad prognosis, display the highest stem cells’ con-
tent (Pece et al, 2010), suggest that high Pin1 levels and activated
Notch foster tumor progression by safeguarding self-renewal and
expansion of their CSCs pool.
The influence of Pin1 on the Notch pathway is likely not limited
to its direct action on Notch proteins. Indeed, among Notch targets
several are also Pin1 substrates (e.g. cyclin D1, NF-jB, Survivin)
(Wulf et al, 2005; Cheng et al, 2013), suggesting that in addition to
its role in sustaining Notch1 protein levels, Pin1 could promote
breast cancer aggressiveness also by enhancing the activity of some
Notch-induced Pin1 targets.
Notch proteins sustain breast CSC and drive breast cancer pro-
gression primarily as a consequence of aberrant levels of their intra-
cellular domains, resulting in constitutive signaling (Ranganathan
et al, 2011). According to the current model, in normal conditions,
after recruitment of p300 acetyl-transferase to the Mastermind-N1-
ICD complex on target promoters, phosphorylation of the N1-ICD
cdc4-phosphodegron causes recognition by the Fbxw7a E3 ubiqu-
itin-ligase, leading to extinction of the Notch cascade as a fail safe
mechanism against prolonged signaling (Ranganathan et al, 2011).
The fact that this event is crucial in switching off the Notch signal,
is witnessed by the significant percentage (more than 50% of the
cases) of T-ALLs that loose this control due to mutations hitting
NOTCH1 or FBXW7 (Ferrando, 2009). Our findings provide new
insights unveiling a mechanism centered on phosphorylation-depen-
dent prolyl-isomerization by Pin1 as responsible for sustained Notch
signaling in breast cancer cells, regardless of Fbxw7a status. We
show that isomerization of N1- and N4-ICD induced by interaction
with Pin1 blocks recognition and degradation by Fbxw7a in a PP2A-
dependent manner.
The impact of Pin1 catalytic activity on Notch proteins goes even
beyond. This isomerase, in fact, also enhances p300-dependent N1-
ICD acetylation (our unpublished observations), a modification
shown to interfere with ubiquitination and degradation of both N1-
and N4-ICD (Guarani et al, 2011; Ranganathan et al, 2011). Pin1
and Notch are even more intertwined than this: Pin1 favors Notch1
cleavage and activation by gamma-secretase (Rustighi et al, 2009)
and, in turn, is a direct transcriptional target of both Notch1 and
Notch4. Hence, deregulated signaling in cancer may fuel a Notch-
Pin1 feed-forward loop, strongly contributing to tumor progression.
Reinforcing this circuitry, the death associated protein kinase 1
(DAPK1), a tumor suppressor found hypermethylated in tumors and
a crucial inhibitor of Pin1 isomerase activity (Lee et al, 2011), was
shown to be repressed by N1-ICD (Li et al, 2008), delineating a pos-
sible scenario in which N1-ICD boosts not only expression but also
activity of Pin1.
The interplay of Pin1 with the two Notch1 and Notch4 receptors
implies its relevance in controlling Notch paralog-specific functions
in the breast. In this respect, since Notch4 was suggested to be rele-
vant in regulating the basal breast SC population, while Notch1
function could be more likely confined to luminal precursors both in
the normal mammary gland as well as in breast cancer (Dontu et al,
2004; Bouras et al, 2008; Raouf et al, 2008; Harrison et al, 2010),
our findings now would place Pin1 as a key regulator of stage-spe-
cific physiologic and pathologic Notch functions in this epithelial
compartment.
Fbxw7a was previously shown to be involved in the mainte-
nance of normal neural, colon and haematopoietic stem cells mostly
through degradation of N1-ICD (Wang et al, 2011). The evidence
that we present here indicates this tumor suppressor as a key nega-
tive force acting against expansion of the breast CSC compartment,
causing degradation of N1- and N4-ICD and potently opposing
breast CSC self-renewal and metastatic spread in vivo. However,
more important to note in this context, is the antagonistic role of
Pin1, which, despite Fbxw7a expression, could revert these effects
by sustaining high levels of N1-ICD and N4-ICD, as depicted in the
model of Fig 8F. Based on the above evidence, it is conceivable that
aberrant expression or activity of Pin1 strongly reduce the selective
pressure for activating mutations in NOTCH genes, or in genes
encoding negative regulators of Notch signaling, such as Fbxw7a.
This likely occurs in breast cancer, where NOTCH1 or FBXW7 mani-
fest low mutational rates (Byrd et al, 2008; Mao et al, 2008; Ibusuki
et al, 2011; Santarpia et al, 2012) and where, instead, high levels of
Pin1 are frequent (Wulf et al, 2001; Girardini et al, 2011) and
strongly correlate with activated N1-ICD. Our data on two different
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groups of breast cancer patients and from a meta-analysis, in which
Notch signaling is constitutively activated despite high levels of
Fbxw7, strongly support this hypothesis.
Besides its pivotal role in controlling transcription as a cofactor
of CSL (CBF1/RBPJ-j /Su(H) Lag1) family of DNA binding proteins,
the ability of Notch to endow breast cancer cells with aggressive
and stemness features results also from the interplay with several
pathways, among them PI3K/Akt, Jak/STAT, NF-kappaB, ErbB2,
Wnt, and HIF1 (Ranganathan et al, 2011). Strikingly, considering
that most of them are also Pin1 substrates (Kim et al, 2008; Liou
et al, 2011) this isomerase may contribute to increase Notch-
induced oncogenesis also by amplifying the signalling emerging
from these cross-talks. In this context, previously described connec-
tions of Notch family members with the p53 pathway (Beverly et al,
2005; Kim et al, 2007; Sun et al, 2010) deserve particular attention.
In mammary stem cells wtp53 has a pivotal role in preventing sym-
metric division and uncontrolled expansion of stem cells (Cicalese
et al, 2009; Insinga et al, 2013). Interestingly, this effect can be
linked, at least in part, to the inhibition of the Notch pathway.
Enhanced mammosphere formation observed by lack of p53, in fact,
can be prevented by treatment with gamma-secretase inhibitors
(Tao et al, 2011).
However not only the emerging roles of p53 in mammary stem
cell biology may have relevant connections to our findings. Wild
type p53 (wtp53), as well as its mutant counterparts (mutp53), in
fact, are well known targets of Pin1 (Wulf et al, 2002; Zacchi
et al, 2002; Zheng et al, 2002; Mantovani et al, 2007; Girardini
et al, 2011; Grison et al, 2011; Sorrentino et al, 2013), raising the
question on whether in the mammary stem cell compartment Pin1
could act in modulating p53 and Notch functions in concert,
unveiling novel intersections between these two pathways. While
in differentiated cells the activity of Pin1 on p53 has been well
characterized in the context of genotoxic stress signaling acting on
the wildtype protein, their interplay in the stem cell compartment
remains to be elucidated. Therefore any consideration would be
premature, even if the evidence that Pin1/ mice have reduced
mammary stem cells (Fig 1C), in contrast with what has been
observed in the TP53/ genotype (Cicalese et al, 2009; Tao et al,
2011), allows to speculate a more complex scenario for a wtp53-
Pin1 interplay in these cells.
On the other hand, also for oncogenic gain of function (GOF)
mutant p53 growing evidence supports a role in promoting cellular
reprogramming and EMT and inciting expansion of mammary epi-
thelial stem cells giving rise to mammary tumors (Sarig et al,
2010; Chang et al, 2011; Dong et al, 2013; Lu et al, 2013). In this
context, we have recently demonstrated a key role of Pin1 in full
unleashing mutp53 GOF in breast cancer (Girardini et al, 2011).
On these bases, it is conceivable that in CSCs lacking wtp53 or
expressing oncogenic mutp53, increased levels of Pin1, due to a
hyperactivated Notch pathway, foster stem cell traits by acting
both on mutp53 oncogenic properties and on Notch itself. In sup-
port of this hypothesis, our analysis revealed that poorly differenti-
ated grade 3 and NDT high-PIN1 high breast cancers are enriched
for the expression of stem cell and mutp53 signature genes (sup-
plementary Table S3).
From a clinical perspective, Pin1 promises to be a critical target
in aggressive breast cancers. Our data demonstrate, in fact, that
Pin1 inhibition, alone or coupled together with chemotherapeutic
agents, could provide the opportunity to hit CSCs, restore chemo-
sensitivity and inhibit metastatic spread.
Materials and Methods
Cell lines and treatments
MDA-MB-231, SK-BR-3, BT-549, and SUM-159 are human breast
carcinoma cells, MCF10A are human normal immortalized epithelial
breast cells, HEK 293T is a human embryonic kidney cell line with
SV40 large T, immortalized Pin1/ fibroblasts have been obtained
by spontaneous immortalization from Mouse Embryo Fibroblasts of
C57BL6/129Sv mixed background (Rustighi et al, 2009). COS-7 are
monkey kidney cells immortalized with SV40 large T antigen. NOP6
is a mouse mammary tumor cell line (Yang et al, 2009). Primary
breast cancer cells from patients were obtained by disaggregation of
surgical samples/biopsies from the Oncology Department at IRCCS
S. Maugeri Foundation in Pavia (Italy). Cell culture media, transfec-
tions, infections and treatments are detailed in supplementary
Data S1.
Isolation and purification of mammary epithelial cells
Mammary glands from 8 to 12-week-old virgin female mice were
enzymatically digested and single cell suspensions of purified mam-
mary epithelial cells were obtained, as described (Sleeman et al,
2006; Stingl et al, 2006). Briefly, Mammary glands from 8 to 12-
week-old virgin female mice were digested for 1–2 h at 37°C in Epi-
Cult-B medium (StemCell Technologies Inc, Vancouver, Canada)
with 600 U/ml collagenase (Sigma-Aldrich, St. Louis, MO, USA) and
200 U/ml hyaluronidase (Sigma). After lysis of the red blood cells
with NH4Cl, the remaining cells were washed with PBS/0.02% w/v
EDTA to allow cell-cell contacts begin to break down. Cells were
then dissociated with 2 ml trypsin 0.25%w/v, 0.2% w/v EDTA for
2 min by gentle pipetting, then incubated in 5 mg/ml Dispase II
(Sigma) plus 1 lg/ml DNase I (Sigma) for 5 min followed by filtra-
tion through a 40 lM cell strainer (BD Falcon, San Jose, CA, USA).
Mammary epithelial cells were then purified using the EasySep
Mouse Mammary Stem Cell Enrichment Kit (StemCell Technologies
Inc).
Flow cytometric analyses and sorting
Mouse mammary epithelial lineage-depleted cells, pre-enriched
using the EasySep Mouse Mammary Stem Cell Enrichment Kit (see
above), were analysed by FACS and sorted with antibodies against
CD49f and CD24. FACS analyses and sorting from mammospheres
based on aldehyde dehydrogenase (Aldh) activity were performed
using the Aldefluor kit (StemCell Technologies Inc) following the
manufacturer’s instructions and are detailed in Supplementary
Information. Sorting of the populations of interest was performed
on ARIA II cell sorter (Beckton Dickinson) to near purity (85%).
Mammosphere cultures
To obtain mammospheres, cells from monolayer cultures were
enzymatically disaggregated (0.05% trypsin–EDTA, Gibco) to a sin-
gle cell suspension, passed though a 40 lm cell strainer (BD
Falcon), plated at clonogenic density (2500 cells/cm2), and grown
in nonadherent culture conditions, as described (Dontu et al, 2003).
In detail, cells were grown for 7–10 days in DMEM:F12 (1:1)
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supplemented with B27 (Invitrogen Corporation, Carlsbad, CA,
USA), 20 ng/ml EGF (PROSPEC, East Brunswick, NJ, USA), 20 ng/
ml bFGF (BD Biosciences, San Jose, CA, USA), 4 lg/ml heparin
(StemCell Technologies Inc.), 0.5 lg/ml hydrocortisone (Sigma)
and 5 lg/ml Insulin (Sigma) in low attachment 24 or 96 well plates
(Coroning) in a humified incubator at 37°C, 5% CO2. Primary mam-
mospheres (≥200 lm) were obtained, collected, counted and again
enzymatically disaggregated as above to re-plate cells at clonogenic
densities to obtain secondary mammospheres. The same procedure
was applied starting from secondary mammospheres to proceed to
tertiary and quaternary mammospheres. Percentages of mammo-
sphere forming efficiencies (%MFE) were calculated as number of
mammospheres divided by the plated cell number and multiplied by
a hundred. Mammospheres were counted with a 20× objective on
an Olympus CK30 microscope (Olympus Italia Srl, Milan, Italy).
Quantitative Real Time PCR (qRT–PCR) analysis
Total RNA from cell lines and xenografts was extracted with QIAzol
Lysis Reagent (Qiagen Srl-Italy, Milan, Italy). Total RNA from for-
malin-fixed, paraffin-embedded samples of breast cancer patients
was extracted starting from 2 to 3 20 lm slices with the HighPure
RNA paraffin Kit (Roche SpA, Monza, Italy) and cDNA was tran-
scribed with QuantiTect (Qiagen) in accordance with the manufac-
turer’s protocols, then amplified on a StepOne Plus cycler (Applied
Biosystems, Life Technologies Europe BV, Monza, Italy), using
SYBR Green Universal PCR Master Mix (Applied Biosystems). His-
tone H3 and GAPDH mRNA were used as internal controls.
Western blot, in vitro binding, and immunoprecipitation
In vitro binding assays, immuno- and co-immunoprecipitations,
Western blot and immunofluorescence analyses were performed
by standard procedures, as described (Rustighi et al, 2009; Girar-
dini et al, 2011), and are detailed in Supplementary Information.
Co-IP experiments were performed in presence of proteasome
inhibitor to avoid misinterpretation of binding results due to pro-
tein degradation.
Ubiquitination analysis (Ni-NTA pull-down)
COS-7 cells were transfected with indicated combinations of vectors
expressing His-Ubiquitin, N1-ICD-myc, Flag-Fbxw7a and control- or
Pin1 specific siRNA. At 48 h post-transfection, cells were treated for
6 h with proteasome inhibitor MG132 (Sigma) and ubiquitin-alde-
hyde (Sigma) to preserve ubiquitin conjugates, then cells were lysed
in highly denaturing conditions with lysis buffer containing 8 M
urea, 0.5% triton and 10 mM imidazole and incubated with Ni2+ ni-
trilotriacetic acid (Quiagen N.1018244) beads for 4 h at room tem-
perature according to manufacturers’ recomendations. Beads were
washed three times with lysis buffer and then analyzed by Western
blot.
Immunohistochemical analyses
Immunohistochemical analyses of mammary tissues from Pin1+/+
and Pin1/ mice and paraffin embedded tissue sections from 43
grade I–III invasive ductal and 38 triple negative breast carcinomas
were performed by standard procedures, as previously described
(Girardini et al, 2011) and are explained in detail in the Supplemen-
tary Information section. Representative bright field images were
taken with a Leica DM4000B microscope (Leica Microsystems S.r.l.,
Milan, Italy). The mouse and human studies were approved respec-
tively by the ethical Committee of the University of Trieste, Italy
(1444DEL12), and by the Institutional Review Ethical Board at the
Hospital of Prato, Istituto Toscano Tumori, Prato, Italy and at the
IRCCS S. Maugeri Foundation in Pavia, Italy.
In vivo tumor growth experiments
For in vivo studies 7 weeks old SCID female mice (Charles River
Laboratories, Lecco, Italy) were used and housed in a specific patho-
gen-free (SPF) animal facility. Procedures involving animals and
their care were in conformity with institutional guidelines (D.L.
116/92 and subsequent complementing circulars) and all experi-
mental protocols were approved by the ethical Committee of the
University of Padua (CEASA). For xenograft studies of breast cancer,
150 000 to 106 cells of indicated MDA-MB-231 clones were resus-
pended in 100 ll of DMEM, injected into the mammary fat pad on
both flanks, of previously anesthetized mice (1–3% isoflurane, Me-
rial Italia S.p.A, Italy). Tumor growth at the injection site was moni-
tored by repeated caliper measurements (Rustighi et al, 2009).
Tumor volume was calculated using the formula: tumor volume
(mm3) = D × d2/2, where D and d are the longest and the shortest
diameters, respectively. After 30 days the animals were anesthetized
and the primary tumors were extracted and directly frozen in liquid
nitrogen to perform molecular analyses. For metastasis studies the
animals were then sacrificed at day 49. At this time point the lymph
nodes and the lungs were excised and paraffin-embedded and for-
malin-fixed (DIAPATH S.P.A., Bergamo, Italy) for hematoxylin-
eosin staining. For limiting dilution experiments data summarizing
the tumor formation were uploaded into the web-based ELDA
(Extreme Limiting Dilution Analysis) statistical software at http://bi-
oinf.wehi.edu.au/software/elda/index.html (Hu & Smyth, 2009),
which uses the frequency of tumor positive and negative animals
at each transplant dose to determine the frequency of self-renewing
cells. For chemotherapy experiments, 1 week after implantation of
the cells, when the tumors became visible, paclitaxel (Taxol,
Bristol-Myers Squibb Italia, Italy) was injected intravenously once
a week at a concentration of 20 mg/ml. The tumors were moni-
tored by measuring with the caliper and after 3 weeks from cells
injection, the mice were sacrificed and the primary tumors were
extracted and collected in PBS. All in vivo tumor growth experi-
ments were conducted according to the UK Coordinating Commit-
tee on Cancer Research (UKCCCR) guidelines 1989 for the welfare
of animals in experimental neoplasia. During in vivo experiments,
animals in all experimental groups were examined daily for a
decrease in physical activity and other signs of disease; severely ill
animals were euthanized.
Statistical analyses
For comparison of mammosphere forming efficencies, mRNA
expression levels, protein half-lives, Co-IP analyses, transfections,
and growth curves the P-values were obtained by applying one-
tailed, type 2 t-test (assuming equal variances) using Microsoft
Excel.
Breast cancer data collection and processing
Twenty-one datasets comprising microarray data of breast cancer
samples and annotations on patients’ clinical outcome were col-
lected. All data were measured on Affymetrix arrays and have
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been downloaded from Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo) and ArrayExpress (http://www.ebi.ac.uk/
arrayexpress/). The complete list of datasets is provided in sup-
plementary Table S1. Prior to analysis, the datasets were reorga-
nized eliminating duplicate samples and samples without
outcome information and each original study was renamed after
the medical center where patients were recruited. The original
studies have been modified as described in detail in supplemen-
tary Data S1. Details on the procedure of Classification of Tumors
into low or high NDT signature groups appear in the Supplemen-
tary Information section.
Survival analysis
To evaluate the prognostic value of the NDT signatures, we esti-
mated, using the Kaplan–Meier method (Kalbfleisch and Prentice),
the probabilities that patients would remain free of death (sur-
vival). To confirm these findings, the Kaplan–Meier curves were
compared using the log-rank or Mantel–Haenszel test (Harrington
and Fleming). P-values were calculated according to the standard
normal asymptotic distribution. NDT and PIN1 signature levels
were obtained as previously described (Adorno et al, 2009).
Survival analyses and Kaplan–Meier plots were obtained using R
survival and survcomp packages. Kaplan–Meier curves have been
compared using the log-rank test of the surv_test function (coin R
package).
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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